Publications

5674 Results

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Authors
J Rosenberg;K Ballman;S Halabi;P Atherton;R Dreicer;C Holmes;W Stadler;E Plimack;T Flaig;R Dreicer;B Teply;J Pincus;S Tagawa;D Vaena;J Misleh;A Shipstone;A Mortazavi;M Morris
Journal / Conference
Journal of Clinical Oncology Aug 1;39(22):2486-2496; May 14;JCO2100286. doi: 10.1200/JCO.21.00286. Online ahead of print
Year
2021
Research Committee(s)
Genitourinary
PMID
PMID33989025
Study Number(s)
CTSU/C90601

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)

Authors
R Cohen;Q Shi;J Meyers;Z Jin;M Svrcek;C Fuchs;F Couture;P Kuebler;J Bendell;A De Jesus-Acosta;P Kumar;D Lewis;B Tan;M Bertagnolli;PA Philip;CD Blanke;E O'Reilly;AF Shields;J Meyerhardt
Journal / Conference
Annals of Oncology, Oct;32(10):1267-1275
Year
2021
Research Committee(s)
Gastrointestinal
PMID
PMID34293461
PMC
PMC8719434
Study Number(s)
CTSU/C80702

Hope, Burnout, and Life Satisfaction: An Intriguing Trinity Among Investigators of the SWOG Cancer Research Network

Authors
D Feldman;M O'Rourke;M Bakitis;R Krouse;H Deiniger;M Hudson;B Corn
Journal / Conference
JCO Oncology Practice Jul;17(7):e908-e916; Apr 26;OP2000990. doi: 10.1200/OP.20.00990. Online ahead of print
Year
2021
PMID
PMID33900801
PMC
PMC8462669

INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer. Toxicity update on first 73 patients

Authors
P Singh;J Efstathiou;C Tangen;S Jhavar;N Hahn;B Costello;S Delacroix;A Tripathi;S Sachdev;J Gills;A Jani;R Bangs;M Plets;N Vogelzang;IM Thompson;F Feng;SP Lerner
Journal / Conference
J Clin Oncol 39, 2021 (suppl 6; abstr 428) (ASCO GU Cancers Symposium (Feb 13-15, 2021 virtual), poster)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1806

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)

Authors
P Black;C Tangen;P Singh;D McConkey;MS Lucia;W Lowrance;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;SP Lerner;I Thompson, Jr.
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4541) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1605

Body Composition Measurements and Overall Survival in Patients with Resectable Pancreatic Adenocarcinoma (SWOG Study S1505)

Authors
D Sohal;M Duong;R Boutin;L Lenchik;J Kim;N Gandhi;MS Beg;A Wang-Gillam;JL Wade;K Guthrie;EG Chiorean;S Ahmad;A Lowy;H Hochster;PA Philip;V Chang
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4131) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Does Adjuvant Chemoradiation Benefit Patients with Lymph Node Positive Biliary Tract Cancers? : A Secondary Analysis of SWOG S0809

Authors
S Gholami;M Duong;D Horowitz;K Guthrie;E Ben-Josef;A El-Khoueiry;CD Blanke;PA Philip;L Kachnic;S Ahmad;F Rocha
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4104) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S0809

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer—toxicity update (Lung-MAP non-matched sub-study S1800A)

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Qian;K Minichiello;DR Gandara;RS Herbst;K Kelly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 9075) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Lung
Study Number(s)
S1800A

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll): Evolve Cll/Sll Study (SWOG S1925; NCT#04269902)

Authors
D Stephens;A Moseley;B Hill;J Pagel;M Shadman;M Fisch;A Danilov;D Ng;A Mato;D Brander;M Othus;S Coutre;S O'Brien;H Erba
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7567) (American Society of Clinical Oncology Annual Meeting 2021 (TIPS), poster session)
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
S1925

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV Non-Small Cell Lung Cancer (Lung-Map Sub-Study): SWOG S1900A

Authors
J Riess;M Redman;P Wheatley-Price;B Faller;L Villaruz;L Corum;A Gowda;G Srkalovic;R Osarogiabon;M Baumgart;L Qian;K Minichiello;DR Gandara;RS Herbst;K Kelly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 9024) (American Society of Clinical Oncology Annual Meeting 2021, poster discussion session)
Year
2021
Research Committee(s)
Lung
Study Number(s)
S1900A